265 related articles for article (PubMed ID: 11600094)
1. Efficacy of fluconazole and itraconazole in the treatment of oral candidiasis in HIV patients.
Menon T; Umamaheswari K; Kumarasamy N; Solomon S; Thyagarajan SP
Acta Trop; 2001 Oct; 80(2):151-4. PubMed ID: 11600094
[TBL] [Abstract][Full Text] [Related]
2. Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV-infected patients.
Chavanet P; Lopez J; Grappin M; Bonnin A; Duong M; Waldner A; Buisson M; Camerlynck P; Portier H
AIDS; 1994 Jul; 8(7):945-50. PubMed ID: 7946104
[TBL] [Abstract][Full Text] [Related]
3. [Fluconazole-resistant Candida species from HIV infected patients with recurrent Candida stomatitis: cross resistance to itraconazole and ketoconazole].
Metzger S; Hofmann H
Mycoses; 1997; 40 Suppl 1():56-63. PubMed ID: 9417515
[TBL] [Abstract][Full Text] [Related]
4. Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients.
Saag MS; Fessel WJ; Kaufman CA; Merrill KW; Ward DJ; Moskovitz BL; Thomas C; Oleka N; Guarnieri JA; Lee J; Brenner-Gati L; Klausner M
AIDS Res Hum Retroviruses; 1999 Nov; 15(16):1413-7. PubMed ID: 10555103
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the fungitest kit by using strains from human immunodeficiency virus-infected patients: study of azole drug susceptibility.
Witthuhn F; Toubas D; Béguinot I; Aubert D; Rouger C; Remy G; Pinon JM
J Clin Microbiol; 1999 Mar; 37(3):864-6. PubMed ID: 9986878
[TBL] [Abstract][Full Text] [Related]
6. Fluconazole resistant opportunistic oro-pharyngeal Candida and non-Candida yeast-like isolates from HIV infected patients attending ARV clinics in Lagos, Nigeria.
Enwuru CA; Ogunledun A; Idika N; Enwuru NV; Ogbonna F; Aniedobe M; Adeiga A
Afr Health Sci; 2008 Sep; 8(3):142-8. PubMed ID: 19357740
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection.
Tumbarello M; Caldarola G; Tacconelli E; Morace G; Posteraro B; Cauda R; Ortona L
J Antimicrob Chemother; 1996 Oct; 38(4):691-9. PubMed ID: 8937963
[TBL] [Abstract][Full Text] [Related]
8. [Antifungal susceptibility testing of commensal and pathogenic clinical isolates of oral Candida].
Zhao M; Zhou ZT
Shanghai Kou Qiang Yi Xue; 2006 Apr; 15(2):218-20. PubMed ID: 16685371
[TBL] [Abstract][Full Text] [Related]
9. A comparative evaluation of Etest and broth microdilution methods for fluconazole and itraconazole susceptibility testing of Candida spp.
Martín-Mazuelos E; Gutiérrez MJ; Aller AI; Bernal S; Martínez MA; Montero O; Quindós G
J Antimicrob Chemother; 1999 Apr; 43(4):477-81. PubMed ID: 10350375
[TBL] [Abstract][Full Text] [Related]
10. Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole.
Martinez M; López-Ribot JL; Kirkpatrick WR; Coco BJ; Bachmann SP; Patterson TF
J Clin Microbiol; 2002 Sep; 40(9):3135-9. PubMed ID: 12202543
[TBL] [Abstract][Full Text] [Related]
11. Iranian HIV/AIDS patients with oropharyngeal candidiasis: identification, prevalence and antifungal susceptibility of Candida species.
Khedri S; Santos ALS; Roudbary M; Hadighi R; Falahati M; Farahyar S; Khoshmirsafa M; Kalantari S
Lett Appl Microbiol; 2018 Oct; 67(4):392-399. PubMed ID: 30019443
[TBL] [Abstract][Full Text] [Related]
12. Response to fluconazole by 23 patients with human immunodeficiency virus infection and oral candidiasis: pharmacological and mycological factors.
Lacassin F; Damond F; Chochillon C; Longuet P; Lebras J; Vilde JL; Leport C
Antimicrob Agents Chemother; 1996 Aug; 40(8):1961-3. PubMed ID: 8843316
[TBL] [Abstract][Full Text] [Related]
13. Oral Candida isolates among HIV-infected subjects in Nigeria.
Nweze EI; Ogbonnaya UL
J Microbiol Immunol Infect; 2011 Jun; 44(3):172-7. PubMed ID: 21524610
[TBL] [Abstract][Full Text] [Related]
14. [Itraconazole suspension in the treatment of HIV-infected patients with fluconazole-resistant oropharyngeal candidiasis and esophagitis].
Eichel M; Just-Nübling G; Helm EB; Stille W
Mycoses; 1996; 39 Suppl 1():102-6. PubMed ID: 8767280
[TBL] [Abstract][Full Text] [Related]
15. In vitro susceptibility and sterol biosynthesis of Candida albicans strains after long-term treatment with azoles in HIV-infected patients.
Hundt W; Hofmann H
Infection; 1994; 22(2):124-31. PubMed ID: 8070926
[TBL] [Abstract][Full Text] [Related]
16. Post-antifungal effect of polyene, azole and DNA-analogue agents against oral Candida albicans and Candida tropicalis isolates in HIV disease.
Anil S; Ellepola AN; Samaranayake LP
J Oral Pathol Med; 2001 Sep; 30(8):481-8. PubMed ID: 11545239
[TBL] [Abstract][Full Text] [Related]
17. Oral Candida albicans isolates with reduced susceptibility to fluconazole in Swedish HIV-infected patients.
Chryssanthou E; Torssander J; Petrini B
Scand J Infect Dis; 1995; 27(4):391-5. PubMed ID: 8658076
[TBL] [Abstract][Full Text] [Related]
18. Fungicidal efficacy of various honeys against fluconazole-resistant Candida species isolated from HIV
Shokri H; Sharifzadeh A
J Mycol Med; 2017 Jun; 27(2):159-165. PubMed ID: 28159362
[TBL] [Abstract][Full Text] [Related]
19. Dynamic analysis of oral Candida carriage, distribution, and antifungal susceptibility in HIV-infected patients during the first year of highly active antiretroviral therapy in Guangxi, China.
Jiang L; Yong X; Li R; Peng Y; Liu W; Qin Q; Zhang L; Liu Z; Liang H; Tao R
J Oral Pathol Med; 2014 Oct; 43(9):696-703. PubMed ID: 24931443
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of rilopirox against fluconazole-susceptible and fluconazole-resistant Candida isolates from patients with HIV infection.
Nenoff P; Taneva E; Pfeil B; Oswald U; Haustein UF
Mycoses; 1999 Apr; 42(1-2):55-60. PubMed ID: 10394849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
